Telix Pharmaceuticals is acquiring Isotope Technologies Munich, or ITM, in a $1.65 billion stock deal that will create a radiopharmaceuticals company with greater global scale. ITM’s lead pipeline asset is in late-stage development for a type of gastrointestinal cancer, where it could compete against Novartis and Curium Pharma products.

The post Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisition appeared first on MedCity News.